<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the development of brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>The animals were subjected to <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> induced by embolization of the right middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) for 60 min </plain></SENT>
<SENT sid="2" pm="."><plain>The brains were studied morphologically 7 days, 1 month, 3 months and 9 months after recirculation </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, the effects of a new calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi>, KB-2796, and a <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, 6,7-dinitroquinoxaline-2,3-dione (DNQX); were evaluated in this model 1 month after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The hemispheric volume of the ipsilateral ischemic side, expressed as a percentage of that on the contralateral non-ischemic side, was 99% in the sham operation group, 94% at 7 days, 87% at 1 month, 68% at 3 months and 65% at 9 months </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_127'>Atrophy</z:mpath> of the striatum and cortex, but not the hippocampus, was observed 1 month after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_127'>Atrophy</z:mpath> of the ipsilateral substantia nigra and the thalamus, which are remote from the ischemic region, was observed 7 days and 1 month, respectively, after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Correlations between the extent of the <z:mpath ids='MPATH_127'>atrophy</z:mpath> in the striatum and that in the substantia nigra and between the extent of the <z:mpath ids='MPATH_127'>atrophy</z:mpath> in the cortex and in the thalamus were statistically significant </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with KB-2796 or DNQX administered intraperitoneally at a dose of 10 mg/kg twice 30 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and immediately after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was effective in reducing the extent of <z:mpath ids='MPATH_127'>atrophy</z:mpath> in both the ipsilateral ischemic and non-ischemic regions </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> on the ipsilateral ischemic side develops time-sequentially after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and that <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> affects not only the primary ischemic focus but also remote regions through transsynaptic connections, and that KB-2796 and DNQX have beneficial effects on <z:mpath ids='MPATH_127'>atrophy</z:mpath> in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>